Does covid make you depressed

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

The Impact of COVID-19 on Depression: A Comprehensive Analysis

Prevalence of Depression During COVID-19

The COVID-19 pandemic has significantly impacted mental health worldwide, with a notable increase in depression rates. A meta-analysis of community-based studies found that the prevalence of depression during the pandemic ranged from 7.45% to 48.30%, with a pooled prevalence of 25% . This is a stark contrast to the global estimated prevalence of depression in 2017, which was 3.44%, indicating that depression rates have increased by approximately seven times during the pandemic .

Post-COVID Depression and Biomarkers

Post-COVID depression is a significant concern, affecting up to 40% of individuals who have recovered from SARS-CoV-2 infection . Research has identified several biomarkers associated with post-COVID depression, including increased levels of interleukin 6 (IL-6), soluble interleukin 6 receptor (sIL-6R), interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α), and decreased levels of brain-derived neurotrophic factor (BDNF) and tryptophan (TRP) . These biomarkers suggest that the etiopathogenesis of post-COVID depression is similar to the inflammatory hypothesis of major depressive disorder (MDD) .

Depression in Post-COVID-19 Syndrome

The persistence of depressive symptoms in individuals recovering from COVID-19 has been documented, with studies reporting that 11-28% of individuals experience depressive symptoms more than 12 weeks post-infection . Clinically significant depression and severe depressive symptoms were observed in 3-12% of these individuals . The severity of acute COVID-19 was not directly associated with the frequency of depressive symptoms, highlighting the need for standardized classification and control groups in future research .

Depression Among Children and Adolescents

The mental health of children and adolescents has also been adversely affected by the pandemic. A meta-analysis revealed that 25.2% of youth globally are experiencing clinically elevated depression symptoms, which is double the pre-pandemic estimates . The prevalence of depression was higher in studies conducted later in the pandemic and among older children and girls .

Pathophysiological Mechanisms Linking COVID-19 and Depression

COVID-19 affects various organs, including the central nervous system, due to its ability to bind to the ACE2 receptor. The disease also triggers a large formation of pro-inflammatory cytokines, which are linked to depressive conditions . This common pathophysiological mechanism suggests that COVID-19 can lead to depressive disorders, especially in severe cases .

Depression in Clinically Stable COVID-19 Patients

Depression is prevalent even among clinically stable COVID-19 patients, with a study reporting a 43.1% prevalence rate . Factors such as having a family member infected with COVID-19, severe infection, male gender, and frequent social media use for COVID-19 information were associated with higher depression rates . Additionally, patients with depression had a lower quality of life compared to those without .

Conclusion

The COVID-19 pandemic has led to a significant increase in depression rates across various populations, including post-COVID patients, children, adolescents, and clinically stable patients. The identification of biomarkers and common pathophysiological mechanisms provides insights into the development of post-COVID depression. Addressing mental health during and after the pandemic is crucial to improve overall well-being and requires coordinated efforts at both national and international levels.

Sources and full results

Most relevant research papers on this topic

Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies

Introduction COVID-19 pandemic, declared on March 11, 2020, constitute an extraordinary health, social and economic global challenge. The impact on people's mental health is expected to be high. This paper sought to systematically review community-based studies on depression conducted during the COVID-19 and estimate the pooled prevalence of depression. Method We searched for cross-sectional, community-based studies listed on PubMed or Web of Science from January 1, 2020 to May 8, 2020 that reported prevalence of depression. A random effect model was used to estimate the pooled proportion of depression. Results A total of 12 studies were included in the meta-analysis, with prevalence rates of depression ranging from 7.45% to 48.30%. The pooled prevalence of depression was 25% (95% CI: 18%−33%), with significant heterogeneity between studies (I 2 =99.60%, p <.001). Conclusions Compared with a global estimated prevalence of depression of 3.44% in 2017, our pooled prevalence of 25% appears to be 7 times higher, thus suggesting an important impact of the COVID-19 outbreak on people's mental health. Addressing mental health during and after this global health crisis should be placed into the international and national public health agenda to improve citizens’ wellbeing.

Meta-AnalysisVery Rigorous JournalHighly Cited

2020·

736citations

·J. Bueno-Notivol et al.

International Journal of Clinical and Health Psychology : IJCHP·

DOI

Biomarkers of Post-COVID Depression

Post-COVID depression is linked to increased levels of inflammatory mediators and decreased brain-derived neurotrophic factors, similar to the leading inflammatory hypothesis of major depressive disorder.

Systematic ReviewRigorous JournalHighly Cited

2021·

85citations

·Piotr Lorkiewicz et al.

Journal of Clinical Medicine·

DOI

Onset and frequency of depression in post-COVID-19 syndrome: A systematic review

Post-COVID-19 syndrome occurs in 11-28% of patients, with clinically-significant depression occurring in 3-12%, but severity of acute COVID-19 is not associated with depressive symptoms.

Systematic ReviewHighly Cited

2021·

325citations

·Olivier Renaud-Charest et al.

Journal of Psychiatric Research·

DOI

Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis.

During COVID-19, 1 in 4 youth globally experienced clinically elevated depression symptoms, while 1 in 5 youth experienced clinically elevated anxiety symptoms.

Meta-AnalysisVery Rigorous JournalHighly Cited

2021·

2216citations

·N. Racine et al.

JAMA pediatrics·

DOI

Is there a common pathophysiological mechanism between COVID-19 and depression?

COVID-19 and depression share common pathophysiological mechanisms, with inflammatory cytokines and ACE-2 receptors playing a role in both conditions.

Systematic Review

2021·

30citations

·Luciano Da Silva Lopes et al.

Acta Neurologica Belgica·

DOI

U.S. Census Bureau‐assessed prevalence of anxiety and depressive symptoms in 2019 and during the 2020 COVID‐19 pandemic

The COVID-19 pandemic had a significant impact on the prevalence of anxiety and depressive disorders in the U.S., with rates increasing by 1.4 and 2.2 percent respectively.

Observational StudyRigorous JournalHighly Cited

2020·

363citations

·J. Twenge et al.

Depression and Anxiety·

DOI

Factors associated with depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic: Clinical implications for U.S. young adult mental health

High levels of loneliness, COVID-19-specific worries, and low distress tolerance are associated with depression, anxiety, and PTSD symptoms in U.S. young adults during the COVID-19 pandemic.

Observational StudyRigorous JournalHighly Cited

2020·

949citations

·Cindy H. Liu et al.

Psychiatry Research·

DOI

Prevalence and Predictors of Depression, Anxiety, and Stress among Youth at the Time of COVID-19: An Online Cross-Sectional Multicountry Study

COVID-19 is increasing the prevalence of depression, anxiety, and stress among youth, with factors like being female, having a friend with mental illness, being quarantined for 14 days, and using the internet as significant predictors.

Observational StudyVery Rigorous JournalHighly Cited

2020·

168citations

·O. Al Omari et al.

Depression Research and Treatment·

DOI

COVID-19 and Depression

Demoralization and depression in COVID-19 patients can be managed with different approaches, but caution is needed when using chloroquine and hydroxychloroquine.

Highly Cited

2020·

109citations

·R. Shader

Clinical Therapeutics·

DOI

Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19

Abstract Introduction : High risk of mental health problems is associated with Coronavirus Disease 2019 (COVID-19). This study explored the prevalence of depressive symptoms (depression hereafter) and its relationship with quality of life (QOL) in clinically stable patients with COVID-19. Methods : This was an online survey conducted in COVID-19 patients across five designated isolation hospitals for COVID-19 in Hubei province, China. Depression and QOL were assessed with standardized instruments. Results : A total of 770 participants were included. The prevalence of depression was 43.1% (95%CI: 39.6%-46.6%). Binary logistic regression analysis found that having family member infected with COVID-19 (OR=1.51, P=0.01), suffering from severe COVID-19 infection (OR=1.67, P=0.03), male gender (OR=0.53, P<0.01), and frequent social media use to obtain COVID-19 related information (OR=0.65, P<0.01) were independently associated with depression. Patients with depression had lower QOL than those without. Conclusion : Depression is highly prevalent in clinically stable patients with COVID-19. Regular screening and appropriate treatment of depression are urgently warranted for this population.

Observational StudyRigorous JournalHighly Cited

2020·

192citations

·Yu-fen Ma et al.

Journal of Affective Disorders·

DOI

Try another search

psychotic symptoms bipolar

depressive disorder in childhood

how can i get rid of a head cold

bipolar disorder therapist

signs of depression in men over 40

how many calories should a normal person eat a day